Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (218)	2/24/1998 9:40:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3559

Hi Rick: >>I quoted a world-famous organic chemist.<< Thanks. I hope you are not serious about this! :) "Worm can* or can of worms are slowly and steady emptying. At the end some of the worms will become butterfly (like from caterpillars). Angio-programs are hot and progressive development (contribution from many research institutions and bts) will bear fruit (in oncology ,cardiovascular and ophthalmology applications). Regards therapeutic proteins, I am for Angio-1 (and now Del-1) and its application in positive angiogenesis. Interesting similarity in aVb3/Tie-2 and Del-1/Angio-1. Curious does aVb3 have natural antagonist (Arg-Gly-Asp motive) like Tie-2? I think that researcher will now search for cross-interaction and synergetic of this two protein/receptor. Maybe exact Tie-1 rule (and its ligands) in angiogenesis is next step. For oncology application I will prefer small molecule inhibitors of the enzymatic activity or receptors antagonist. Hope REGN brooded collaboration with PCOP (they are full of screening candidates). Regards the Progenitor, can they perform target validation for Del-1, or their work is oriented toward basic science (genomic) and discovery collaboration with research institutions? mz